These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 12539065)

  • 1. Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China.
    Lu EY; Chen HH; Zhao H; Ozawa S
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing invasive pneumococcal disease in children.
    Clover RD
    J Am Board Fam Pract; 2003; 16(5):464-5. PubMed ID: 14645339
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vojicic J; Grajales AG; Cane A
    Vaccine; 2023 Jun; 41(27):3949-3950. PubMed ID: 36797099
    [No Abstract]   [Full Text] [Related]  

  • 4. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.
    Morrow A; De Wals P; Petit G; Guay M; Erickson LJ
    Can J Infect Dis Med Microbiol; 2007 Mar; 18(2):121-7. PubMed ID: 18923713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modelling to accurately quantify the benefits of pneumococcal conjugate vaccine.
    Shrestha S; Shrestha A
    Lancet Glob Health; 2024 Sep; 12(9):e1377-e1378. PubMed ID: 39151965
    [No Abstract]   [Full Text] [Related]  

  • 6. Notes from the Field: A Cluster of Multi-Strain Invasive Pneumococcal Disease Among Persons Experiencing Homelessness and Use of Pneumococcal Conjugate Vaccine - El Paso County, Colorado, 2022.
    Callaway J; Durbin K; Zachary H; Barnes MM; Kobayashi M; Chochua S; Gayou N; Albanese B
    MMWR Morb Mortal Wkly Rep; 2023 Nov; 72(46):1277-1278. PubMed ID: 37971930
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunization in Canada: Update for 2015.
    MacDougall DM; Halperin SA
    J Can Chiropr Assoc; 2016 Mar; 60(1):6-12. PubMed ID: 27069261
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost savings of pneumococcal vaccination in children with nephrotic syndrome in a low-middle-income country.
    Mathew G; Gracy E; Muliyil DE
    Pediatr Nephrol; 2024 Oct; 39(10):3125-3126. PubMed ID: 38691153
    [No Abstract]   [Full Text] [Related]  

  • 9. A perspective on vaccine evaluation research in Canada: Past and future.
    Scheifele DW; Tingle AJ
    Can J Infect Dis; 1993 Mar; 4(2):79-83. PubMed ID: 22346426
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic evaluations of vaccines in Canada: a scoping review.
    Rafferty ERS; Gagnon HL; Farag M; Waldner CL
    Cost Eff Resour Alloc; 2017; 15():7. PubMed ID: 28484344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevnar 7 Childhood Immunization Program and Serotype Replacement: Changes in Pneumococcal Incidence and Resulting Impact on Health Care Costs in Alberta (2003-2008).
    Waye A; Chuck AW; Jacobs P; Tyrrell G; Kellner JD
    Drugs Real World Outcomes; 2015 Jun; 2(2):153-161. PubMed ID: 27747768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools.
    Chaiyakunapruk N; Somkrua R; Hutubessy R; Henao AM; Hombach J; Melegaro A; Edmunds JW; Beutels P
    BMC Med; 2011 May; 9():53. PubMed ID: 21569402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
    Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
    Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.
    McClure CA; Ford MW; Wilson JB; Aramini JJ
    Can J Infect Dis Med Microbiol; 2006 Jan; 17(1):19-26. PubMed ID: 18418479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing bacterial disease in the HIV-infected of sub-Saharan Africa: the role of cotrimoxazole and the pneumococcal vaccines.
    Spencer DC
    Curr HIV/AIDS Rep; 2007 Aug; 4(3):141-6. PubMed ID: 17884000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.